Gibson Eddie, Ollendorf Daniel A, Simoens Steven, Bloom David E, Martinón-Torres Federico, Salisbury David, Severens Johan Louis, Toumi Mondher, Molnar Daniel, Meszaros Kinga, Sohn Woo-Yun, Begum Najida
Wickenstones Ltd, Abingdon, UK.
Institute for Clinical Research and Health Policy Studies (ICRHPS), Center for the Evaluation of Value and Risk in Health (CEVR), Tufts Medical Center, Boston, MA, USA.
J Mark Access Health Policy. 2023 Aug 10;11(1):2239557. doi: 10.1080/20016689.2023.2239557. eCollection 2023.
The benefits of preventive interventions lack comprehensive evaluation in standard health technology assessments (HTA), particularly for rare and transmissible diseases. To identify possible considerations for future HTA using analogies between the treatment and prevention of rare diseases. An Expert panel meeting assessed whether one HTA assessment framework can be applied to assess both rare disease treatments and preventive interventions. Experts also evaluated the range of value elements currently included in HTAs and their applicability to rare, transmissible, and/or preventable diseases. A broad range of value should be considered when assessing rare, transmissible disease prevention. Although standard HTA can be applied to transmissible diseases, the risk of local outbreaks and the need for large-scale prevention programs suggest a modified assessment framework, capable of incorporating prevention-specific value elements in HTAs. A 'Rule of Prevention' framework was proposed to allow broader value considerations anchored to severity, equity, and prevention benefits in decision-making for preventive interventions for rare transmissible diseases. The proposed prevention framework introduces an explicit initial approach to consistently assess rare transmissible diseases, and to incorporate the broader value of preventive interventions compared with treatment.
预防性干预措施的益处,在标准的卫生技术评估(HTA)中缺乏全面评估,尤其是针对罕见病和传染病。通过类比罕见病的治疗与预防,确定未来HTA可能需要考虑的因素。一次专家小组会议评估了一个HTA评估框架是否可用于同时评估罕见病治疗和预防性干预措施。专家们还评估了当前HTA中所包含的价值要素范围及其对罕见病、传染病和/或可预防疾病的适用性。在评估罕见病、传染病的预防时,应考虑广泛的价值。虽然标准的HTA可应用于传染病,但局部爆发的风险以及大规模预防计划的需求表明,需要一个经过修改的评估框架,该框架能够在HTA中纳入预防特有的价值要素。提出了一个“预防规则”框架,以便在针对罕见传染病的预防性干预措施决策中,基于严重性、公平性和预防效益进行更广泛的价值考量。所提议的预防框架引入了一种明确的初始方法,以持续评估罕见传染病,并纳入与治疗相比预防性干预措施的更广泛价值。